Augmented and standard Berlin–Frankfurt–Münster chemotherapy for treatment of adult acute lymphoblastic leukemia

References

• Copelan E A, McGuire E A. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995; 85: 1151–1168
   PubMed Web of Science ®Google Scholar
• Pui C H, Relling M V, Downing J R. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535–1548
   PubMed Web of Science ®Google Scholar
• Laport G F, Larson R A. Treatment of adult acute lymphoblastic leukemia. Semin Oncol 1997; 24: 70–82
   PubMed Web of Science ®Google Scholar
• Riehm H, Gadner H, Henze G, Kornhuber B, Langermann H J, Müller-Weihrich S, . Acute lymphoblastic leukemia: treatment results in three BFM studies (1970–81). Leukemia Research: Advances in Cell Biology and Treatment, S B Murphy, J R Gilbert, et al. Elsevier Science Publishing, New York 1983; 251–263
   Google Scholar
• Riehm H, Langermann H J, Gadner H, Odenwald E, Henze G. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970–1976. Am J Pediatr Hematol Oncol 1980; 2: 299–306
   Google Scholar
• Gaynon P S, Steinherz P G, Bleyer W A, Albin A R, Albo V C, Finkelstein J Z, et al. Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features: early conclusions of study CCG-106 by the children's cancer study group. Lancet 1988; 22: 921–924
   Google Scholar
• Henze G, Langermann H J, Bramswig J, Breu H, Gadner H, Schellong G, et al. The BFM 76/79 acute lymphoblastic leukemia therapy study. Klin Padiatr 1981; 193: 145–154
   PubMed Web of Science ®Google Scholar
• Nachman J, Sather H N, Gaynon P S, Lukens J N, Wolff L, Trigg M E. Augmented Berlin–Frankfurt–Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the children's cancer group. J Clin Oncol 1997; 15: 2222–2230
   PubMed Web of Science ®Google Scholar
• Nachman J B, Sather H N, Sensel M G, Trigg M E, Cherlow J M, Lukens J N, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998; 338: 1663–1671
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Thiel E, Loffler H, Bodenstein H, Plaumann L, Buchner T, et al. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 1984; 64: 38–44
   PubMed Web of Science ®Google Scholar
• Rowe J M, Buck G, Burnett A K, Chopra R, Wiernik P H, Richards S M, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106: 3760–3767
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Thiel E, Löffler H, Büchner T, Ganser A, Heil G, et al. Prognostic factors in a multicentric study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123–131
   PubMed Web of Science ®Google Scholar
• Larson R A, Dodge R K, Burns C P, Lee E J, Stone R M, Schulman P, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85: 2025–2037
   PubMed Web of Science ®Google Scholar
• Gaynor J, Chapman D, Little C, McKenzie S, Miller W, Andreeff M, et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial hospital experience since 1969. J Clin Oncol 1988; 6: 1014–1030
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
   PubMedGoogle Scholar
• Annino L, Vegna M L, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863–871
   PubMed Web of Science ®Google Scholar
• Linker C A, Levitt L J, O'Donnell M, Forman S J, Ries C A. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991; 78: 2814–2822
   PubMed Web of Science ®Google Scholar
• Hussein K K, Dahlberg S, Head D, Waddell C C, Dabich L, Weick J K, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73: 57–63
   PubMed Web of Science ®Google Scholar
• Schauer P, Arlin Z A, Mertelsmann R, Cirrincione C, Friedman A, Gee T S, et al. Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol 1983; 1: 462–470
   PubMed Web of Science ®Google Scholar
• Taylor P R, Reid M M, Bown N, Hamilton P J, Proctor S J. Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. Blood 1992; 80: 1813–1817
   PubMed Web of Science ®Google Scholar
• Chessells J M, Hall E, Prentice H G, Durrant J, Bailey C C, Richards S M. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC paediatric and adult working parties. Leukemia 1998; 12: 463–473
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Hoelzer D, Arnold R, Böhme A, Bartram C R, Freund M, et al. Treatment of adult ALL according to protocols of the German multicenter study group for adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307–1325
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, O'Brien S, Smith T L, Cortes J, Giles F J, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 13: 547–561
   Google Scholar
• Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 2464–2471
   PubMed Web of Science ®Google Scholar
• Thiebaut A, Vernant J P, Degos L, Huguet F R, Reiffers J, Sebban C, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation: a follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000; 14: 1353–1365
   PubMed Web of Science ®Google Scholar
• Thomas X, Boiron J-M, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 20: 4075–4086
   Web of Science ®Google Scholar
• Fielding A K, Richards S M, Chopra R, Lazarus H M, Litzow M R, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12/ECOG 2993 study. Blood 2007; 109: 944–950
   PubMed Web of Science ®Google Scholar
• Goldstone A H, Richards S M, Lazarus H M, Tallman M S, Buck G, Fielding A K, et al. In adults with f-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the international ALL trial (MRC UK ALL XII/ECOG E2993). Blood 2008; 111: 1827–1833
   PubMed Web of Science ®Google Scholar
• Stock W, La M, Sanford B, Bloomfield C D, Vardiman J W, Gaynon P, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of children's cancer group and cancer and leukemia group B studies. Blood 2008; 112: 1646–1654
   PubMed Web of Science ®Google Scholar
• Boissel N, Auclerc M F, Lhéritier V, Perel Y, Thomas X, Leblanc T, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774–780
   PubMed Web of Science ®Google Scholar
• De Bont J M, van der Holt B, Dekker A W, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcomes for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004; 18: 2032–2053
   PubMed Web of Science ®Google Scholar
• Nachman J. Clinical characteristics, biological features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol 2005; 130: 166–173
   PubMed Web of Science ®Google Scholar
• Vitale A, Guarini A, Chiaretti S, Foá R. The changing scene of adult acute lymphoblastic leukemia. Curr Opin Oncol 2006; 18: 652–659
   PubMed Web of Science ®Google Scholar